Objective: Abdominal aortic aneurysms often coexist with reduced lung function and chronic obstructive pulmonary disease (COPD). These conditions are each associated with cigarette smoking, cardiovascular disease, and evidence of increased inflammatory and hemostatic activity. The aim of this study was to determine if these factors accounted for the link between aneurysms and pulmonary disease. Methods: The design was a case-control study comparing patients with an asymptomatic abdominal aortic aneurysm with population-based controls without an aneurysm. Aneurysms were diagnosed by ultrasound scan, and pulmonary function was measured by respiratory questionnaire and spirometry. Activation of inflammation and hemostasis was measured by assay of plasma interleukin-6 (IL-6), fibrinogen, von Willebrand factor (vWF), tissue plasminogen activator ( 
Reduced lung function occurs more commonly in patients with abdominal aortic aneurysms (AAAs) [1] [2] [3] [4] [5] and is related to an increased risk of rupture. [6] [7] [8] Atherosclerotic cardiovascular diseases such as coronary heart disease, peripheral arterial disease, and stroke are also associated with impaired lung function [9] [10] [11] [12] and with the occurrence of AAAs. 13 Thus, cardiovascular disease could be a major confounding factor for the association between lung function and aneurysm. Likewise, cigarette smoking is an important risk factor for respiratory disease, cardiovascular disease, and AAA 13 and could have a role in explaining the association between lung function and aneurysm.
Inflammation is an important component of aneurysmal disease as well as chronic respiratory disease and atherosclerosis. In patients with an AAA, proinflammatory cytokines have shown increased expression in aneurysmal aortic tissue 14 and higher circulating levels than in controls without an AAA. 15 Increased cytokine activity may induce degradation of components of the extracellular matrix in the arterial wall leading to aneurysm formation 16 and, furthermore, may enhance coagulation by, for example, upregulation of plasma fibrinogen. The association between reduced lung function and aortic aneurysm could conceivably be mediated or due to a concomitant effect of systemic inflammation and hemostasis.
The aim of this study was to determine whether an association between impaired lung function and AAA was independent or was influenced by the effects of smoking, cardiovascular disease, and markers of activated inflammation and hemostasis.
METHODS
The study design was a case-control study comparing cases of asymptomatic AAA with controls without an aneurysm. This investigation was nested partly within the Edinburgh Artery Study, a population cohort study that began in 1988. At baseline, 1592 men and women aged 55 to 74 years were selected randomly from the general population from the age-sex registers of 11 general practices in the City of Edinburgh. Subjects attended a clinic for a comprehensive examination that included measurement of cardiovascular risk factors and disease. Follow-up examinations were conducted at 5 and 12 years and included ultrasound screening for AAAs. Continuous assessment to monitor cardiovascular events took place during the follow-up period. Further details of the design of the Edinburgh Artery Study have been published. [17] [18] [19] The study was approved by the Lothian Health Board Ethics Committee.
The recruitment target was 100 cases and 100 controls, especially to ensure a reasonably representative sample of asymptomatic aneurysms. The intention was to select most cases from the Edinburgh Artery Study, but owing to the low numbers identified, most cases were selected consecutively from the elective surgical waiting list at the Royal Infirmary of Edinburgh.Cases were included if they had an anteroposterior aortic diameter of at least 3 cm confirmed at the study clinic. The aortic diameter was measured by ultrasound scan using a 3 MHz transducer and an ATL UM9 HDI (Bothell, Wash) system, and the maximum of three readings was taken as the diameter. The few cases derived from the Edinburgh Artery Study were identified at the 12-year examination. An Aloka 500 portable scanner (Tokyo, Japan) was used in the homes of a few subjects who were unable to attend the clinic.
Controls were all selected from within the Edinburgh Artery Study population. Potential controls were stratified into 5-year age and sex groups, and matched controls were randomly selected from these strata by using random number tables. They were oversampled to allow for nonattendance at the clinic. Ultrasound screening at the 12-year examination confirmed the absence of aortic aneurysm.
Cases and controls also completed a questionnaire on smoking the World Health Organization (WHO) questionnaire inquiring about angina, intermittent claudication, and previous myocardial infarction 20 ; and the Medical Research Council questionnaire was used for respiratory symptoms. 21 Height was measured without shoes to the nearest 5 mm by using a stadiometer, weight was measured without outer clothing to the nearest 100 g using a digital scale (Soehnle, Murrhardt, Germany). Respiratory function, determined by forced expiratory volume in 1 second (FEV 1 ), forced vital capacity (FVC), and peak expiratory flow rate (PEFR), was measured three times by using a hand-held spirometer (Vitalograph Ltd, Buckingham, United Kingdom). Systolic and diastolic blood pressure was measured in the right arm by using a Hawksley random zero sphygmomanometer (Sussex, United Kingdom) and systolic pressures in the right and left ankles with the aid of a Doppler ultrasound probe (Sonicaid, Sussex, United Kingdom). A 12-lead electrocardiogram (ECG) was recorded. A 20-mL venous blood sample was taken without tourniquet, centrifuged, and aliquots of citrated plasma were stored at Ϫ40 o C. These measures were included in the Edinburgh Artery Study 12-year examination with the exception of the respiratory symptoms and lung function tests, which were assessed only for this case-control study.
In the laboratory, the following markers of activated inflammation and hemostasis were measured: plasma interleukin-6 (IL-6) by high sensitivity enzyme-linked immunoabsorbent assay (ELISA) (R & D Systems, Minneapolis, Minn), fibrinogen (Clauss assay), von Willebrand factor (vWF) (ELISA, DAKO, Glostrup, Denmark), tissue plasminogen activator (tPA) antigen, fibrin D-dimer, and plasmin-antiplasmin complexes (ELISAs, Biopool, Ventura, Calif). The selection of factors was dependent on assays conducted at the 12-year follow-up examination in the Edinburgh Artery Study. C-reactive protein (CRP) was assayed only at baseline 12 years earlier and was therefore not included in the current analysis; assays were not available for serum proteases including matrix metalloproteinases.
Measures of respiratory function consisted of PEFR, FEV 1 , FVC, and the FEV 1 /FVC ratio as well as the percentage of subjects with values derived from a healthy reference population of known age, sex, height, and ethnic group. 22 The maximum value of the three repeat respiratory tests was used in the analyses. A history of respiratory symptoms suggestive of chronic bronchitis was considered to be present if a positive response was given to questions on the usual occurrence of cough or phlegm first thing in the morning in winter or of wheeze (attacks of wheezing or whistling in the chest). 21 A modification of the Global Initiatives for Chronic Obstructive Lung Disease (GOLD) definitional criteria 23 was used to classify subjects into the mutually exclusive categories of severe COPD (FEV 1 /FVC Ͻ0.7 and FEV 1 Ͻ50% predicted), moderate COPD (FEV 1 /FVC Ͻ0.7 and FEV 1 50% to Ͻ80% predicted), mild COPD (FEV 1 /FVC Ͻ0.7 and FEV 1 Ն80% predicted), symptoms only (presence of symptoms in absence of lung function abnormality), restrictive lung disease (FEV 1 Ն0.7 and FVC Ͻ80% predicted), or no lung disease (none of the above).
Cigarette-smoking status was defined by the three categories of current, ex, and never. Lifetime cigarette consumption was analyzed by pack-years (number of years smoked ϫ average number of packs smoked per day). The distribution was skewed with a few heavy smokers, and so a square root transformation was used. Body mass index (BMI) was calculated as kg/m 2 . The ankle brachial index (ABI) was calculated for each leg by dividing ankle pressure by arm systolic pressure and the lower of the left and right indices was used in the analysis. The presence of cardiovascular disease was defined as any one of the following: myocardial infarction (any two of positive WHO question-naire, or subject remembering that a doctor had diagnosed myocardial infarction, or ECG evidence), angina (positive WHO questionnaire plus either ECG evidence of ischemia or subject remembering that a doctor had diagnosed angina), or intermittent claudication (positive WHO questionnaire). Diabetes mellitus was not specified in the analysis because of very small numbers in the study sample.
The analysis was carried out according to a predetermined statistical plan by using SPSS version 12 (SPSS, Chicago, Ill) for Windows (Microsoft, Redmond, Wash) and consisted of a comparison of clinical and blood assay data between cases and controls. Logistic regression was used to assess univariate differences in risk factors between cases and controls. The distributions of plasma fibrinogen, tPA and vWF were skewed, and so square root transformations were used. A natural log transformation was used for D-dimer, IL-6, and plasmin anti-plasmin complexes. Logistic regression was used to calculate age, sex, and heightadjusted odds ratios for aneurysm according to lung function and severity of COPD. Those with restrictive lung disease were excluded from this analysis because it is a type of disease different from COPD. Odds ratios were further adjusted for inflammatory and hemostatic factors, smoking, and cardiovascular disease. Throughout all analyses, a twosided P Ͻ .05 was used to denote statistical significance. A variable was considered to have a possible confounding effect if the odds ratio changed by Ն20%.
RESULTS
The study sample comprised 89 cases of asymptomatic AAA, of which 81 were selected from the waiting list for elective aneurysm repair in the Royal Infirmary of Edinburgh and eight were identified by ultrasound scanning in the Edinburgh Artery Study. Of the 139 controls selected, 98 attended for examination. No controls were subsequently found to have an aneurysm. The median aneurysm diameter (interquartile range) of cases was 4.5 cm (3.9 to 5.1 cm) and controls, 2.0 cm (1.8 to 2.3 cm).
The demographic, risk factor, and cardiovascular status of the cases and controls is shown in Table I . The mean age of all subjects was 73.5 years, and 72% were men. As expected from the matching scheme, no significant differences in age or sex were found between cases and controls. BMI was lower in cases than controls (P ϭ .03), whereas systolic blood pressure and a history of cigarette smoking were significantly higher in cases (P ϭ .01). Indicators of cardiovascular disease were also more common in cases (P ϭ .01). About one third of cases had evidence of previous myocardial infarction, angina, or claudication. The mean ABI was significantly lower in cases than in controls (P Ͻ .001).
Plasma levels of fibrinogen, IL-6, plasmin antiplasmin complexes, and D-dimer were significantly higher in aneurysm cases than controls (Table II) . The differences in median levels of IL-6 (P Ͻ .001), plasmin antiplasmin complexes (P ϭ .01), and D-dimer (P Ͻ .001) were substantial. Table III shows that lung function was worse in aneurysm cases than in controls. FVC was slightly but nonsignificantly reduced, whereas the measures of expiratory flow (FEV 1 and PEFR) were significantly reduced (P Ͻ .01), resulting in a lower FEV 1 /FVC ratio in cases than in controls (0.67 vs 0.75, P Ͻ .001). Similar differences were found for the predicted results according to age, sex, and height. The frequency of COPD was also found to differ between cases and controls (P Ͻ .001), with more cases having severe, moderate, or mild COPD relative to no lung disease compared with controls.
The extent to which the difference in lung function tests between cases and controls was independent of markers of activated inflammation and hemostasis, cigarette smoking, and the presence of cardiovascular disease is demonstrated in the logistic regression models shown in Table IV . The odds ratios for aneurysm (95% confidence intervals [CI]) for a one standard deviation decrease in FEV 1 , PEFR, and FEV 1 / FVC, adjusting for age, sex, and height, were each Ͼ2 (P Ͻ .01). Adjusting for cardiovascular disease or cigarette smoking had no important effect on the odds ratios. Adjusting for each of the inflammatory and hemostatic markers, only plasmin antiplasmin complexes and D-dimer had a confounding effect, reducing odds ratios by Ն20%. The most notable effect was for D-dimer. Adjusting for all the inflammatory and hemostatic markers also had a substantial effect, reducing the odds ratios to nonsignificant levels. Further adjustment for smoking, cardiovascular disease, and ABI had little effect. Table V shows similar effects of the markers of activated inflammation and hemostasis, smoking, and cardiovascular disease on the relationships between increasing severity of COPD on the risks of aneurysm. Lifetime smoking and cardiovascular disease had little influence on the magnitude of the odds ratio. Plasmin antiplasmin complexes and Ddimer were the only markers that had a specified confounding effect in reducing the odds of aneurysm for increasing severity of COPD. The combined effect of all the inflammatory and hemostatic markers was comparable. Further adjustment for smoking, cardiovascular disease, and ABI had little effect.
Finally, in logistic regressions on aortic aneurysm, which included one measure of lung function in each model and all inflammatory and hemostatic factors, smoking, cardiovascular disease, and ABI, D-dimer was found to be strongly and independently related to aneurysm in each model. The odds ratio (95% CI) for one SD increase in D-dimer in each model was 5.9 (2.7, 12.6) with FEV 1 , 5.1 (2.5, 10.6) with PEFR; 4.6 (2.3, 9.5) with FEV 1 /FVC, and 5.0 (2.4, 10.3) with COPD (all P Ͻ .001).
DISCUSSION
The principal findings of this study were that individuals with an AAA had worse lung function and more COPD than controls without AAAs. The lung function affected was primarily obstructive (reduced expiration) and not restrictive (reduced vital capacity). Aneurysm cases had higher levels of cigarette smoking, cardiovascular disease, and plasma levels of markers of inflammation and hemostasis. The associations between lung function, COPD, and aneurysms were only marginally affected by smoking and cardio- vascular disease but were substantially changed and became nonsignificant on adjusting for the markers of inflammation and hemostasis.
Our results confirm the findings of other clinical 1,2 and community studies [3] [4] [5] showing an association between COPD and AAAs. In veterans screened in the United States, 3 men born in 1914 in Malmo, 4 and in a population cross-sectional study in Denmark, 5 evidence of COPD was related to an increased risk of aneurysm. Impaired lung function was found in a case-control study in Japan 1 to be more common in cases of thoracic and abdominal aneurysms than in coronary heart disease patients and healthy controls.
The degree of respiratory impairment may be important; in a consecutive group of emphysema patients, those with the lowest FEV 1 /FVC had a higher prevalence of aneurysms than those with a moderate reduction. 2 Chronic pulmonary disease has also been related to the risk of aneurysm rupture in autopsy series 6 and in the follow-up of aneurysm patients, 7, 8 although, surprisingly, reduced aneurysm growth was found in one study. 5 However, the overall evidence indicates that an association does exist between impaired lung function and the presence of AAAs.
AAAs occur frequently in the presence of atherosclerosis 13 and its clinical manifestations. [9] [10] [11] [12] Reduced expiratory flow has been associated longitudinally with a higher incidence of fatal and nonfatal coronary heart disease and stroke. [9] [10] [11] Furthermore, impaired lung function has been associated with subclinical cerebral infarction and white matter lesions 24 as well as carotid stenosis and a low ABI. 12 We have shown, however, that the association between both reduced expiratory flow (FEV 1 and PEFR) and COPD with the risk of aortic aneurysm was independent of concomitant cardiovascular disease. The Aneurysm Detection And Management (ADAM) study 3 in the United States also found the association to be independent of atherosclerotic diseases; in a Danish study, the association became nonsignificant on adjustment for cardiovascular diseases, but this may have been due to the small numbers involved. 5 Cigarette smoking is a strong risk factor for AAA. The risk is greater than, and independent of, the effect of smoking on coronary heart disease. 13, 25 Smoking is a common cause of COPD and therefore may be a confounding factor for the association between impaired lung function and aneurysm. We found, however, that the relationship between lung function (FEV 1 , PEFR, and FEV 1 /FVC) and COPD with risk of aneurysm was independent of lifetime cigarette smoking. An effect independent of a history of smoking regularly was also found in the ADAM study. 3 The association of impaired pulmonary function with aneurysm rupture has also been shown to be independent of smoking. 7, 8 This independence does not, of course, rule out some effect of smoking on both lung function and aneurysm contributing to the association, perhaps mediated by a common pathway such as inflammation.
Inflammation and activation of hemostasis (resulting in a laminated luminal thrombosis) are important characteristics of AAAs. An inflammatory infiltrate, including lymphocytes and macrophages, is present in the aneurysm adventitia and media and is associated with increased breakdown of the extracellular matrix. 16 Aneurysms have also been shown to contain/secrete excess inflammatory cytokines, including IL-6, 14 which may enhance proteolysis in the aneurysm wall. 26 These cytokines increase the expression of matrix metalloproteinase (MMP-9) in macrophages, which are the primary source of this elastolytic proteinase 16 and are becoming recognized as having an important role in the pathobiology of aneurysms. 27 Circulating levels of cytokines, including IL-1␤, IL-6, and tumor necrosis factor-␣, have also been found to be higher in patients with aneurysms than in those with coronary heart disease or healthy controls. 15 Inflammatory cytokines are associated with increased production of acute phase proteins such as C-reactive protein and fibrinogen that are elevated in the plasma of aneurysm patients. 28, 29 The extent to which systemic activation of inflammation and hemostasis is a cause or consequence (or both) of aneurysm formation is unclear, however.
The role of systemic activation of inflammation and hemostasis in explaining the increased risk of coronary heart disease in those with COPD was investigated in the Third National Health and Nutrition Examination Survey (NHANES) in the United States. 30 A reduced FEV 1 was associated with higher plasma fibrinogen and C-reactive protein levels, confirming that activated inflammation and hemostasis in COPD had both a low-grade systemic and local effect. COPD and C-reactive protein were found to have an additive effect in predicting risk of cardiac injury. Higher levels of inflammatory proteins associated with impaired lung function have been shown to occur independently of smoking, and it has been suggested that genetic polymorphisms predisposing to exaggerated inflammatory responses may also be relevant. 31 Nevertheless, the increased risk of atherosclerotic cardiovascular disease in those with COPD may be only partly related to inflammation. Other factors, such as high blood pressure and diabetes mellitus, which also occur more commonly in those with COPD, may be important. 32, 33 The inflammatory and hemostatic factor that had the largest effect in reducing the association between impaired lung function and aortic aneurysm was D-dimer, an indicator of fibrin formation and degradation. We have shown in earlier analyses of the Edinburgh Artery Study population that D-dimer levels were higher in aneurysm cases than controls, 29 and this has been confirmed in subsequent studies in Japan. 34, 35 Plasmin antiplasmin complexes, an indicator of fibrinolytic activation, also had a considerable confounding effect on the associations between lung function and aneurysms. Plasmin is a common activator of proteolytic systems in aneurysmal degradation of the aortic wall, and plasmin antiplasmin complexes have been shown to be predictive of the rate of aneurysm growth. 36 To our knowledge, plasmin antiplasmin complex levels have not been reported in relation to COPD, but given that most inflammatory processes disturb the balance in coagulation and fibrinolysis, it would not be surprising if plasmin antiplasmin complex levels were elevated, as has been shown in patients with bronchial asthma.
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CONCLUSION
The association of reduced respiratory function in aneurysm cases in this study was not explained by either cigarette smoking or cardiovascular disease but became nonsignificant on adjusting for markers of inflammation and hemostasis. We hypothesize that response to injury (activation of inflammation and hemostasis) may be an explanation of the association. We suggest further studies (eg, of genotypes influencing inflammatory responses) to test this hypothesis. The influence of inflammatory and hemostatic factors on the association could, however, simply reflect an epiphenomenon in which these factors are a marker for unknown biologic effects leading to formation of aneurysm and lung disease.
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